{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-193353","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.306008+00:00","generated_at":"2026-05-17T08:57:17.286781+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Maze Therapeutics appoints Misbah Tahir as CFO, effective Sep 2, 2025","bullets":["Misbah Tahir appointed CFO, previously CFO of IGM Biosciences (Jan 2019–Aug 2025).","Annual base salary of $500,000, discretionary bonus up to 40% of base salary.","One-time sign-on bonus of $50,000 (clawback if service <1 year) and option for 325,000 shares.","Option vests 25% on first anniversary, then 1/48th monthly; severance includes 9 months base salary plus benefits.","Enhanced severance on termination without cause or for good reason within 3 months before/12 months after change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-193353","json":"https://secwatch.observer/filing/0001193125-25-193353.json","markdown":"https://secwatch.observer/filing/0001193125-25-193353.md","text":"https://secwatch.observer/filing/0001193125-25-193353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525193353/0001193125-25-193353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525193353/d11864d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:57:17.286781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}